Katherine S Virgo1, R Bryan Rumble2, Ronald de Wit3, David S Mendelson4, Thomas J Smith5, Mary-Ellen Taplin6, James L Wade7, Charles L Bennett8, Howard I Scher9, Paul L Nguyen6, Martin Gleave10, Scott C Morgan11, Andrew Loblaw12, Sean Sachdev13, David L Graham14, Neha Vapiwala15, Amy M Sion16, Virgil H Simons17, James Talcott18. 1. Emory University, Atlanta, GA. 2. American Society of Clinical Oncology, Alexandria, VA. 3. Erasmus MC, Rotterdam, NL. 4. Virginia G Piper Cancer Network, Scottsdale, AZ. 5. Johns Hopkins Medicine, Baltimore, MD. 6. Dana-Farber Cancer Institute, Boston, MA. 7. Cancer Care Specialists of Illinois, Decatur, IL. 8. University of South Carolina College of Pharmacy, Columbia, SC. 9. Memorial Sloan Kettering Cancer Center & Weill Cornell Medical College, New York, NY. 10. University of British Columbia, Vancouver, BC, Canada. 11. The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada. 12. Sunnybrook Health Sciences Centre, Toronto, ON, Canada. 13. Northwestern University, Chicago, IL. 14. Levine Cancer Institute, Charlotte, NC. 15. University of Pennsylvania, Philadelphia, PA. 16. Medical University of South Carolina, Charleston, SC. 17. The Prostate Net, Sanford, NC. 18. Nanhealth, Inc, Culver City, CA.
Abstract
PURPOSE: Update all preceding ASCO guidelines on initial hormonal management of noncastrate advanced, recurrent, or metastatic prostate cancer. METHODS: The Expert Panel based recommendations on a systematic literature review. Recommendations were approved by the Expert Panel and the ASCO Clinical Practice Guidelines Committee. RESULTS: Four clinical practice guidelines, one clinical practice guidelines endorsement, 19 systematic reviews with or without meta-analyses, 47 phase III randomized controlled trials, nine cohort studies, and two review papers informed the guideline update. RECOMMENDATIONS: Docetaxel, abiraterone, enzalutamide, or apalutamide, each when administered with androgen deprivation therapy (ADT), represent four separate standards of care for noncastrate metastatic prostate cancer. Currently, the use of any of these agents in any particular combination or series cannot be recommended. ADT plus docetaxel, abiraterone, enzalutamide, or apalutamide should be offered to men with metastatic noncastrate prostate cancer, including those who received prior therapies, but have not yet progressed. The combination of ADT plus abiraterone and prednisolone should be considered for men with noncastrate locally advanced nonmetastatic prostate cancer who have undergone radiotherapy, rather than castration monotherapy. Immediate ADT may be offered to men who initially present with noncastrate locally advanced nonmetastatic disease who have not undergone previous local treatment and are unwilling or unable to undergo radiotherapy. Intermittent ADT may be offered to men with high-risk biochemically recurrent nonmetastatic prostate cancer. Active surveillance may be offered to men with low-risk biochemically recurrent nonmetastatic prostate cancer. The panel does not support use of either micronized abiraterone acetate or the 250 mg dose of abiraterone with a low-fat breakfast in the noncastrate setting at this time.Additional information is available at www.asco.org/genitourinary-cancer-guidelines.
PURPOSE: Update all preceding ASCO guidelines on initial hormonal management of noncastrate advanced, recurrent, or metastatic prostate cancer. METHODS: The Expert Panel based recommendations on a systematic literature review. Recommendations were approved by the Expert Panel and the ASCO Clinical Practice Guidelines Committee. RESULTS: Four clinical practice guidelines, one clinical practice guidelines endorsement, 19 systematic reviews with or without meta-analyses, 47 phase III randomized controlled trials, nine cohort studies, and two review papers informed the guideline update. RECOMMENDATIONS: Docetaxel, abiraterone, enzalutamide, or apalutamide, each when administered with androgen deprivation therapy (ADT), represent four separate standards of care for noncastrate metastatic prostate cancer. Currently, the use of any of these agents in any particular combination or series cannot be recommended. ADT plus docetaxel, abiraterone, enzalutamide, or apalutamide should be offered to men with metastatic noncastrate prostate cancer, including those who received prior therapies, but have not yet progressed. The combination of ADT plus abiraterone and prednisolone should be considered for men with noncastrate locally advanced nonmetastatic prostate cancer who have undergone radiotherapy, rather than castration monotherapy. Immediate ADT may be offered to men who initially present with noncastrate locally advanced nonmetastatic disease who have not undergone previous local treatment and are unwilling or unable to undergo radiotherapy. Intermittent ADT may be offered to men with high-risk biochemically recurrent nonmetastatic prostate cancer. Active surveillance may be offered to men with low-risk biochemically recurrent nonmetastatic prostate cancer. The panel does not support use of either micronized abiraterone acetate or the 250 mg dose of abiraterone with a low-fat breakfast in the noncastrate setting at this time.Additional information is available at www.asco.org/genitourinary-cancer-guidelines.
Authors: Lisa Marie Ruppert; Erica Dayan Cohn; Niamh M Keegan; Abigail Bacharach; Sungmin Woo; Theresa Gillis; Howard I Scher Journal: JCO Oncol Pract Date: 2022-02-17
Authors: Michael J Morris; Jose Mauricio Mota; Kristine Lacuna; Patrick Hilden; Martin Gleave; Michael A Carducci; Fred Saad; Erica D Cohn; Julie Filipenko; Glenn Heller; Neal Shore; Andrew J Armstrong; Howard I Scher Journal: Eur Urol Oncol Date: 2021-05-18
Authors: Mario Rivera-Izquierdo; Virginia Martínez-Ruiz; José Juan Jiménez-Moleón Journal: Int J Environ Res Public Health Date: 2022-01-27 Impact factor: 3.390
Authors: Stephen J Freedland; Rickard Sandin; Janvi Sah; Birol Emir; Qiao Mu; Anna Ratiu; Agnes Hong; Lucile Serfass; Scott T Tagawa Journal: Cancer Med Date: 2021-11-02 Impact factor: 4.452
Authors: Juho Jasu; Teemu Tolonen; Emmanuel S Antonarakis; Himisha Beltran; Susan Halabi; Mario A Eisenberger; Michael A Carducci; Yohann Loriot; Kim Van der Eecken; Martijn Lolkema; Charles J Ryan; Sinja Taavitsainen; Silke Gillessen; Gunilla Högnäs; Timo Talvitie; Robert J Taylor; Antti Koskenalho; Piet Ost; Teemu J Murtola; Irina Rinta-Kiikka; Teuvo Tammela; Anssi Auvinen; Paula Kujala; Thomas J Smith; Pirkko-Liisa Kellokumpu-Lehtinen; William B Isaacs; Matti Nykter; Juha Kesseli; G Steven Bova Journal: Eur Urol Open Sci Date: 2021-07-02